Standout Papers

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients Wit... 2000 2026 2008 2017 923
  1. Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma (2000)
    Mark R. Middleton, Jean‐Jacques Grob et al. Journal of Clinical Oncology

Immediate Impact

7 by Nobel laureates 23 from Science/Nature 63 standout
Sub-graph 1 of 24

Citing Papers

Probiotic neoantigen delivery vectors for precision cancer immunotherapy
2024 StandoutNature
Exploring tissue architecture using spatial transcriptomics
2021 StandoutNature
2 intermediate papers

Works of J. Weiss being referenced

Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
2000 Standout

Author Peers

Author Last Decade Papers Cites
J. Weiss 885 140 51 544 238 8 1.1k
Uwe Fraass 703 80 21 582 253 13 1.1k
Susan Bakke 711 141 74 812 121 12 1.4k
M. Thomas 739 47 83 499 230 17 1.1k
Vijay Peddareddigari 592 146 40 705 112 18 1.1k
Nida Iqbal 570 88 24 521 124 11 1.3k
Michelle L. Kraus 438 93 50 461 97 9 1.0k
B Soehnlen 512 84 50 581 124 15 1.2k
A. Coates 794 40 50 670 241 19 1.3k
Erin McNamara 613 91 63 331 361 18 952
Robert W. Hsieh 637 67 43 589 421 8 1.3k

All Works

Loading papers...

Rankless by CCL
2026